H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium

• Published in: International journal of gynecological cancer Vol. 14; no. 3; p. 521
• Main Authors: Tanos, V, Ariel, I, Prus, D, De-Groot, N, Hochberg, A
• Format: Journal Article
• Language: English
• Published: England 01-05-2004
• Subjects: Case-Control Studies; Endometrial Hyperplasia - genetics; Endometrial Neoplasms - genetics; Female; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor II - genetics; RNA, Long Noncoding; RNA, Messenger - analysis; RNA, Neoplasm - analysis; RNA, Untranslated - genetics
• ISSN: 1048-891X
• DOI: 10.1111/j.1048-891x.2004.014314.x

We examined H19 and insulin-like growth factor 2 (IGF2) gene expression in normal endometrium (12 cases), hyperplasia (27 cases), and cancer (27 cases) by non-radioactive in situ hybridization. H19 was not expressed in the epithelium of normal endometrium, but its frequency of expression was 15% in hyperplastic and 60% in neoplastic epithelium. In stroma cells, H19 frequency of expression was 75% in normal endometrium, 55% in hyperplasia, and 37% in carcinoma. According to the grade of endometrial cancer cell differentiation, H19 showed increased frequency and level of expression in the epithelium from well to moderately and poorly differentiated tissues. Our results indicate that H19 expression in epithelial cells of endometrial hyperplasia and cancer merits further investigation and could be useful as a complementary histopathologic and prognostic marker among other modalities in endometrial cancer. IGF2 expression did not appear useful for diagnostic or prognostic purposes.